The Trump Administration’s plans to move Medicare Part B drugs into the Part D system would mean additional delays and cost barriers for patients.

Biosimilars had their big break in the US in 2015, but three years later biosimilars are still struggling to make a mark.

Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.

New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.

Artificial intelligence could have a huge impact on drug discovery.

WHO is investigating the potential of certain biosimilars in a prequalification pilot program.

Initially, The American College of Rheumatology was cautious about biosimilars, but times have changed.

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

Why does the full potential of biosimilars remain untapped? Four experts weigh in.